This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Teva Pharmaceuticals International Gmbh. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: Michael J Lamson: Innovator in Pain Management
Introduction
Michael J Lamson is a notable inventor based in Cary, NC (US). He has made significant contributions to the field of pain management through his innovative approaches. His work primarily focuses on developing effective treatments for postherpetic neuralgia, a condition that can cause severe pain following shingles.
Latest Patents
Michael J Lamson holds a patent for "Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound." This patent describes methods for treating postherpetic neuralgia in mammals using a pharmaceutical composition that includes a spiro-oxindole compound. The methods outlined in the patent provide excellent penetration of the compound into the affected skin area, effectively reducing the severity of the neuralgia while minimizing systemic exposure.
Career Highlights
Lamson is associated with Teva Pharmaceuticals International GmbH, where he continues to work on innovative solutions for pain management. His expertise in pharmaceutical formulations has positioned him as a key player in the development of new treatments.
Collaborations
Throughout his career, Lamson has collaborated with notable colleagues, including Michael Fetell and Richard Malamut. These partnerships have contributed to the advancement of his research and the successful development of his patented methods.
Conclusion
Michael J Lamson's contributions to the field of pain management through his innovative patent demonstrate his commitment to improving the quality of life for those suffering from postherpetic neuralgia. His work continues to influence the pharmaceutical industry and offers hope for effective treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
